Page 38 - Read Online

Page 110 Oquendo et al. J Transl Genet Genom 2021;5:89-111 https://dx.doi.org/10.20517/jtgg.2021.04

85. Froimchuk E, Jang Y, Ge K. Histone H3 lysine 4 methyltransferase KMT2D. Gene 2017;627:337-42. DOI PubMed PMC
86. Zhang J, Dominguez-Sola D, Hussein S, et al. Disruption of KMT2D perturbs germinal center B cell development and promotes
lymphomagenesis. Nat Med 2015;21:1190-8. DOI PubMed PMC
87. Green MR, Kihira S, Liu CL, et al. Mutations in early follicular lymphoma progenitors are associated with suppressed antigen
presentation. Proc Natl Acad Sci U S A 2015;112:E1116-25. DOI PubMed PMC
88. Okosun J, Bödör C, Wang J, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the
initiation and progression of follicular lymphoma. Nat Genet 2014;46:176-81. DOI PubMed PMC
89. Phan RT, Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 2004;432:635-9.
DOI PubMed
90. Han L, Madan V, Mayakonda A, et al. Chromatin remodeling mediated by ARID1A is indispensable for normal hematopoiesis in
mice. Leukemia 2019;33:2291-305. DOI PubMed PMC
91. Trøen G, Nygaard V, Jenssen T, et al. Constitutive expression of the AP-1 transcription factors c-jun, junD, junB, and c-fos and the
marginal zone B-Cell transcription factor notch2 in splenic marginal zone lymphoma. J Mol Diagn 2004;6:297-307. DOI PubMed
PMC
92. Ruiz-Ballesteros E, Mollejo M, Rodriguez A, et al. Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic
markers identified after tissue and cDNA microarray analysis. Blood 2005;106:1831-8. DOI PubMed
93. Navarro A, Clot G, Martínez-Trillos A, et al. Improved classification of leukemic B-cell lymphoproliferative disorders using a
transcriptional and genetic classifier. Haematologica 2017;102:e360-3. DOI PubMed PMC
94. Robinson JE, Greiner TC, Bouska AC, Iqbal J, Cutucache CE. Identification of a Splenic Marginal Zone Lymphoma Signature:
Preliminary Findings With Diagnostic Potential. Front Oncol 2020;10:640. DOI PubMed PMC
95. Duran-ferrer M, Clot G, Nadeu F, et al. The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical
outcome. Nat Cancer 2020;1:1066-81. DOI
96. Queirós AC, Beekman R, Vilarrasa-Blasi R, et al. Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the
Entire B Cell Lineage. Cancer Cell 2016;30:806-21. DOI PubMed PMC
97. Kulis M, Merkel A, Heath S, et al. Whole-genome fingerprint of the DNA methylome during human B cell differentiation. Nat Genet
2015;47:746-56. DOI PubMed PMC
98. Kulis M, Heath S, Bibikova M, et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic
lymphocytic leukemia. Nat Genet 2012;44:1236-42. DOI PubMed
99. Lee ST, Muench MO, Fomin ME, et al. Epigenetic remodeling in B-cell acute lymphoblastic leukemia occurs in two tracks and
employs embryonic stem cell-like signatures. Nucleic Acids Res 2015;43:2590-602. DOI PubMed PMC
100. Su IH, Basavaraj A, Krutchinsky AN, et al. Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement.
Nat Immunol 2003;4:124-31. DOI PubMed
101. Akasaka T, Tsuji K, Kawahira H, et al. The Role of mel-18, a Mammalian Polycomb Group Gene, during IL-7-Dependent
Proliferation of Lymphocyte Precursors. Immunity 1997;7:135-46. DOI PubMed
102. Oakes CC, Seifert M, Assenov Y, et al. DNA methylation dynamics during B cell maturation underlie a continuum of disease
phenotypes in chronic lymphocytic leukemia. Nat Genet 2016;48:253-64. DOI PubMed PMC
103. Ziller MJ, Gu H, Müller F, et al. Charting a dynamic DNA methylation landscape of the human genome. Nature 2013;500:477-81.
DOI PubMed PMC
104. Jiang Y, Hatzi K, Shaknovich R. Mechanisms of epigenetic deregulation in lymphoid neoplasms. Blood 2013;121:4271-9. DOI
PubMed PMC
105. Solé C, Arnaiz E, Lawrie CH. MicroRNAs as Biomarkers of B-cell Lymphoma. Biomark Insights 2018;13:1177271918806840. DOI
PubMed PMC
106. Watkins AJ, Hamoudi RA, Zeng N, et al. An integrated genomic and expression analysis of 7q deletion in splenic marginal zone
lymphoma. PLoS One 2012;7:e44997. DOI PubMed PMC
107. Ruiz-Ballesteros E, Mollejo M, Mateo M, Algara P, Martínez P, Piris MA. MicroRNA losses in the frequently deleted region of 7q in
SMZL. Leukemia 2007;21:2547-9. DOI PubMed
108. Karaayvaz M, Zhai H, Ju J. miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer. Cell
Death Dis 2013;4:e659. DOI PubMed PMC
109. Scarola M, Schoeftner S, Schneider C, Benetti R. miR-335 directly targets Rb1 (pRb/p105) in a proximal connection to p53-
dependent stress response. Cancer Res 2010;70:6925-33. DOI PubMed
110. Di Lisio L, Sánchez-Beato M, Gómez-López G, et al. MicroRNA signatures in B-cell lymphomas. Blood Cancer J 2012;2:e57. DOI
PubMed PMC
111. Bouteloup M, Verney A, Rachinel N, et al. MicroRNA expression profile in splenic marginal zone lymphoma. Br J Haematol
2012;156:279-81. DOI PubMed
112. Peveling-Oberhag J, Crisman G, Schmidt A, et al. Dysregulation of global microRNA expression in splenic marginal zone lymphoma
and influence of chronic hepatitis C virus infection. Leukemia 2012;26:1654-62.
113. Cervetti G, Galimberti S, Sordi E, et al. Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal
zone lymphoma (SMZL). Ann Oncol 2010;21:851-4. DOI PubMed
114. Phillips TJ, Corradini P, Gurion R, et al. Phase 2 study evaluating the efficacy and safety of parsaclisib in patients with relapsed or
refractory marginal zone lymphoma (CITADEL-204). Blood 2020;136:27-8. DOI
115. Opat S, Tedeschi A, Linton K, et al. Efficacy and safety of zanubrutinib in patients with relapsed/refractory marginal zone